Get the Stockscreener App
48.13
0.86%
0.41
Pre-market:
48.50
0.37
+0.77%
Scholar Rock Holding Corp stock is traded at $48.13, with a volume of 852.22K.
It is up +0.86% in the last 24 hours and up +1.69% over the past month.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
See More
Previous Close:
$47.72
Open:
$47.9
24h Volume:
852.22K
Relative Volume:
0.58
Market Cap:
$5.77B
Revenue:
$47.30M
Net Income/Loss:
$-377.94M
P/E Ratio:
-14.05
EPS:
-3.4256
Net Cash Flow:
$-300.64M
1W Performance:
-2.47%
1M Performance:
+1.69%
6M Performance:
+19.70%
1Y Performance:
+58.01%
1-Day Range:
$47.59
$48.78
1-Week Range:
$46.01
$49.72
52-Week Range:
$27.07
$51.62
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Name
Scholar Rock Holding Corp
Sector
Industry
Phone
857-259-3860
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
48.13 | 5.72B | 47.30M | -377.94M | -300.64M | -3.4256 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Jan-09-26 | Initiated | Citigroup | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-09-25 | Initiated | BofA Securities | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-15-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Resumed | Jefferies | Buy |
| Jul-30-25 | Resumed | Raymond James | Strong Buy |
| Jul-17-25 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-26-24 | Reiterated | H.C. Wainwright | Buy |
| Oct-07-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-24 | Initiated | Raymond James | Strong Buy |
| Oct-25-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Overweight |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jul-12-22 | Initiated | Truist | Buy |
| Mar-23-22 | Initiated | H.C. Wainwright | Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Mar-12-20 | Initiated | Robert W. Baird | Outperform |
View All
Scholar Rock Holding Corp Stock (SRRK) Latest News
SRRK Stock Price, Quote & Chart | SCHOLAR ROCK HOLDING CORP (NASDAQ:SRRK) - ChartMill
103,191 Shares in Scholar Rock Holding Corporation $SRRK Bought by Fideuram Intesa Sanpaolo Private Banking S.P.A. - MarketBeat
Biotech Scholar Rock to webcast Jefferies healthcare talk June 3 - Stock Titan
Three Biotechs That Are Top Takeover Targets - Yahoo Finance
iA Global Asset Management Inc. Makes New $5.43 Million Investment in Scholar Rock Holding Corporation $SRRK - MarketBeat
Charles Schwab Investment Management Inc. Acquires 25,060 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock reports new employee inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Redmile Group owns 7.6% of Scholar Rock (SRRK) via funds and affiliates - Stock Titan
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
T. Rowe Price holds 5.4% of Scholar Rock (NASDAQ: SRRK) - Stock Titan
Earnings call transcript: Scholar Rock Q1 2026 sees EPS miss, stock rises - Investing.com Nigeria
Earnings call transcript: Scholar Rock Q1 2026 sees EPS miss, stock rises By Investing.com - Investing.com South Africa
Transcript : Scholar Rock Holding Corporation Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 08 - marketscreener.com
HC Wainwright Has Positive View of Scholar Rock Q2 Earnings - MarketBeat
A Look At Scholar Rock (SRRK) Valuation After FDA Acceptance Of Apitegromab BLA - Sahm
State of New Jersey Common Pension Fund D Buys New Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
TradingKey - TradingKey
Number of shareholders of Scholar Rock Holding Corp. – FWB:2QK - TradingView
FY2029 EPS Estimates for Scholar Rock Increased by Analyst - MarketBeat
Scholar Rock (SRRK) Q1 2026 Earnings Transcript - AOL.com
Nan Fung Trinity HK Ltd. Buys 225,603 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
Vanguard Group Inc. Boosts Stake in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q1 2026 Earnings Call Transcript - Insider Monkey
Scholar Rock Q1 Earnings Call Highlights - MarketBeat
Scholar Rock (NASDAQ:SRRK) Issues Quarterly Earnings Results - MarketBeat
SRRK Maintained by Barclays -- Price Target Raised to $55 - GuruFocus
Scholar Rock anticipates apitegromab approval by September 30 as FDA accepts SMA BLA with two fill-finish sites - MSN
Scholar Rock (SRRK) Receives Positive Catalyst Watch from JPMorg - GuruFocus
SRRK Maintained by HC Wainwright & Co. -- Price Target Raised to $65 - GuruFocus
UBS Group AG Sells 226,355 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
A Look At Scholar Rock (SRRK) Valuation After Strong Multi Year Shareholder Returns - Yahoo Finance
Transcript : Scholar Rock Holding Corporation, Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
Scholar Rock Q1 2026 Earnings Call Transcript - MarketBeat
Earnings call transcript: Scholar Rock’s Q1 2026 financial resilience amid earnings miss By Investing.com - Investing.com South Africa
Earnings call transcript: Scholar Rock’s Q1 2026 financial resilience amid earnings miss - Investing.com Nigeria
Scholar Rock Advances Apitegromab Toward Potential 2026 Launches - TipRanks
Earnings Flash (SRRK) Scholar Rock Posts Q1 Net Loss $0.83 a Share, vs. FactSet Est of $0.80 Loss - marketscreener.com
Q1 2026 Scholar Rock Holding Corp Earnings Call Transcript - GuruFocus
Scholar Rock (NASDAQ: SRRK) details March 31 2026 quarter - Stock Titan
Scholar Rock (SRRK) boosts cash to $480M as FDA sets apitegromab PDUFA date - Stock Titan
Scholar Rock gets Sept. 30 FDA decision date for SMA drug - Stock Titan
Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights - Business Wire
MSN Money - MSN
Scholar Rock faces earnings test as apitegromab approval looms By Investing.com - Investing.com South Africa
Scholar Rock faces earnings test as apitegromab approval looms - Investing.com
Evercore ISI initiates Scholar Rock stock coverage with outperform rating By Investing.com - Investing.com Australia
Scholar Rock Holding Corp Stock (SRRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):